Use to assess genetic risk of abnormal drug metabolism for drugs metabolized by CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, and CYP3A5. May aid in drug selection and dose planning for many drugs. For testing that includes GeneDose access, refer to Cytochrome P450 Genotyping Panel, with GeneDose Access (3004255).
Polymerase Chain Reaction/Fluorescence Monitoring/Sequencing
If reflexed: 5-7 additional days are required for LR-PCR and sequencing.
New York DOH Approval Status
Lavender (K2EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Couseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
Whole blood is the preferred specimen type. Saliva samples that yield inadequate DNA quality and/or quantity will be reported as inconclusive if test performance does not meet laboratory-determined criteria for reporting. Saliva is only validated for the OpenArray and CNV portions of testing and not the long-range PCR/duplication testing. Long-range PCR/duplication testing will not be performed for saliva samples.
If long-range PCR/duplication testing is performed, additional charges will apply. Approximately less than 5% of samples require 2D6 copy number determination.
81225; 81226; 81227; 81230; 81231; 81479; if reflexed, add 81479
|Component Test Code*||Component Chart Name||LOINC|
|3001525||CYP PANEL Specimen||66746-9|
|3001526||CYP PANEL Interpretation||50398-7|
|3004499||CYP2C Cluster Geno|
|3004500||CYP2C Cluster Pheno||81259-4|
- CYP2C cluster